Targets › EPCAM
4 programs from 4 companies in 7 trials: 5 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Immunology, Other; next expected readout Nov 2026.
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. (UniProt, P16422)
Open in Phaseline: the race on EPCAM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Wuhan YZY Biopharma | M701 anti-EpCAM and anti-CD3 human-mouse chimeric bispecific antibody | EPCAM, CD3E | Phase 3 | Malignant Ascites; Malignant Pleural Effusions | Dec 2026 |
| Mirador Therapeutics | Adecatumumab (MT-201) Epithelial cell adhesion molecule inhibitor | EPCAM | Phase 2 | Inflammatory Bowel Disease (IBD); Healthy Volunteer | Nov 2026 |
| AcadeMab Biomedical | AM-928 anti-EpCAM monoclonal antibody | EPCAM | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| BioAtla | BA3182 Conditionally active bispecific T-cell engager (BiTE) antibody targeting EpCAM and CD3 | EPCAM, CD3E | Phase 1 | Advanced Adenocarcinoma | Sep 2028 |
Healthy Volunteer (2) Malignant Ascites (1) Malignant Pleural Effusions (1) Advanced Solid Tumor (1) Inflammatory Bowel Disease (IBD) (1) Advanced Adenocarcinoma (1)
small molecule (3), protein or peptide (1)
Wuhan YZY Biopharma (1) AcadeMab Biomedical (1) Mirador Therapeutics (1) BioAtla (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.